Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 17;10(2):e02049-21. doi: 10.1128/spectrum.02049-21

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Gou et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PMC Copyright notice

FIG 8 — IL-6 prevents GSDME- and GSDMD-mediated lung inflammation injury during pneumococcal pneumosepsis. (A and B) Caspase-3 (n = 4/group), GSDME (n = 4/group), IL-1β (n = 4/group), and (C and D) caspase-1 (n = 4/group), GSDMD (n = 4/group), and IL-18 (n = 4/group) in lungs of mice with or without IL-6 protein treatment during pneumococcal pneumosepsis, as indicated. IL-1β and TNF-α in (E) lung homogenates (n = 6/group) and (F) BALF (n = 5 to 6/group) of mice with or without IL-6 protein treatment during pneumococcal pneumosepsis, as indicated. (G to I) Lung inflammation injury in mice with or without IL-6 protein treatment was assessed in situ using (G) a commercial cell death detection kit (n = 3/group), (H) H&E staining (n = 3/group), and (I) total protein in BALF (n = 4 to 7/group) during pneumococcal pneumosepsis.